Breathe Well Live Well
|
Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at …
Benzinga Prior to joining Pieris Dr. Fitzgerald held senior positions at Argenta Discovery and Pulmagen Therapeutics, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, she was employed … |
View full post on asthma – Google News
DNAinfo |
Asthma Study Results to Be Presented at Public Meeting in Englewood
DNAinfo According to the nonprofit Merck Childhood Asthma Network in Washington, D.C., asthma-related hospitalizations in Englewood and West Englewood are among the highest in Chicago, at 60 percent and 71 percent of hospitalizations in the area, more than … |
View full post on asthma – Google News
|
Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at …
News-Medical.net Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM™ therapeutic, the first treatment developed utilizing its iSPERSE™ inhaled drug platform, will be … |
View full post on asthma – Google News
|
KALBITOR(R) (ecallantide) Data Presented at American Academy of Allergy …
MarketWatch (press release) (NASDAQ:DYAX) today announced the presentation of data from KALBITOR(R) (ecallantide) clinical studies in hereditary angioedema (HAE) at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in Orlando, Florida. |
View full post on asthma – Google News
|
KALBITOR (ecallantide) Data in HAE Presented at the American College of …
PharmaLive.com (press release) (NASDAQ: DYAX) announced today that two oral and two poster presentations featuring KALBITOR® (ecallantide) data in hereditary angioedema (HAE) were presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting held … KALBITOR(R) (ecallantide) Data in HAE Presented at the American College of … |
View full post on asthma – Google News
|
KALBITOR® (ecallantide) Data in HAE Presented at the American College of …
Business Wire (press release) (NASDAQ: DYAX) announced today that two oral and two poster presentations featuring KALBITOR ® (ecallantide) data in hereditary angioedema (HAE) were presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting held … KALBITOR(R) (ecallantide) Data in HAE Presented at the American College of … |
View full post on asthma – Google News
|
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American …
PR Newswire (press release) There can be no assurance that that the data presented during the 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting regarding Cinryze is predictive of how Cinryze will perform in commercial usage. … |
View full post on asthma – Google News
|
KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy …
Trading Markets (press release) Ecallantide for Treatment of Acute Attacks of Acquired C1 Esterase Inhibitor Deficiency — Nisha S. Patel, MD, Asthma Allergy & Pulmonary Associates, … Dyax to present data of KALBITOR inhibitor for Angioedema at ACAAI Meeting |
View full post on asthma – Google News
|
KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy …
istockAnalyst.com (press release) … at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting held November 11-16, at the Phoenix Convention Center in Phoenix, AZ. … KALBITOR(R) (ecallantide) Data Presented at the American College of Allergy … |
View full post on asthma – Google News
|
Cinryze(R) (C1 esterase inhibitor [human]) Data Presented at 2010 Annual …
Investor’s Business Daily … MD, of Allergy, Asthma, and Dermatology Associates in Lake Oswego, Ore. discussed the experience of 14 pregnant women who were enrolled in pivotal and … Cinryze® (C1 esterase inhibitor [human]) Data Presented at 2010 Annual Meeting … |
View full post on asthma – Google News